Meropenem Hikma (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to a weakened cell wall, osmotic instability, and ultimately bacterial cell death. Its structure also confers resistance to many β‑lactamases, extending its activity to multidrug‑resistant pathogens.

The dosing regimen for Meropenem Hikma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Healthcare professionals adjust the dose and infusion rate to achieve optimal therapeutic levels while minimizing toxicity.

Safety data for Meropenem in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. Breastfeeding mothers should consult a healthcare provider before use.

To request Meropenem Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers a broader activity against Pseudomonas aeruginosa and certain resistant Enterobacteriaceae. Unlike ertapenem, which lacks reliable activity against Pseudomonas, meropenem is often preferred for hospital‑acquired pneumonia and severe sepsis where Pseudomonas coverage is essential.

Meropenem Hikma should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Proper cold‑chain handling ensures stability and potency until reconstitution for intravenous administration.

Meropenem Hikma is supplied as a sterile powder for reconstitution and is administered intravenously. After reconstitution with the appropriate diluent, the solution is infused over a specified period, typically 15‑30 minutes, under the supervision of qualified healthcare personnel. Infusion rates may be adjusted based on renal function and clinical response.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, Clostridioides difficile‑associated colitis, severe hypersensitivity reactions such as anaphylaxis, and significant hematologic abnormalities like neutropenia or thrombocytopenia. Prompt recognition and medical intervention are essential if these events occur.

Meropenem Hikma is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving concomitant valproic acid, unless benefits outweigh the risks.